ArticleLiver international : official journal of the International Association for the Study of the Liver2026
Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparing of Efficacy and Safety Between Sintilimab Plus IBI305 and PD-1 Inhibitor Plus TKIs in Combination of TACE for uHCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic therapy combined with transcatheter arterial chemoembolization (TACE) is the main treatment strategy for patients with unresectable hepatocellular carcinoma (uHCC). Nevertheless, there are currently few direct comparative studies between different combined treatment regimens. Therefore, this study aims to compare the efficacy and safety of sintilimab and bevacizumab biosimilar (IBI305) versus PD-1 inhibitor and tyrosine kinase inhibitor (TKI) combined with TACE in the treatment of uHCC.
methodsThis retrospective study included 225 patients with uHCC who received either TACE combined with sintilimab and IBI305 (TSB group, n = 84) or other PD-1 inhibitors and TKIs (TTP group, n = 141). This study evaluated overall survival (OS) as the primary outcome, with secondary endpoints encompassing progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR)and treatment-related adverse events (TRAEs). To mitigate potential confounding biases across the two cohorts, propensity score matching (PSM) was employed.
resultsFollowing PSM, 136 uHCC patients were included, with 68 in both the TSB and TTP groups. There was no statistical difference in OS (p = 0.18) or PFS (p = 0.34) between the TSB group and the TTP group. According to both RECIST1.1 and mRECIST criteria, there were no notable changes in ORR or DCR. Both groups demonstrated manageable toxicity profiles. Subgroup analysis suggested that whereas patients with large tumours (HR, 0.33; p = 0.024), solitary lesions (HR, 0.16; p < 0.001) or portal vein tumour thrombosis (HR, 0.43; p = 0.033) derived greater survival benefit from the TSB regimen, those with multifocal tumours (HR, 1.86; p = 0.033) benefited more from the TTP regimen.
conclusionsThe TSB and TTP regimens offer comparable efficacy and safety in uHCC, yet the TSB regimen appears to offer greater benefit in specific patient subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.